Humane Therapeutics Through Crosslinking


Bastion biologics

Receptor Crosslinking

Safer oncology outcomes

 
 
Artboard 15.jpg
 

Meet Audrey


She loves drawing and playing with her friends. Audrey started experiencing night sweats, fever and fatigue three months ago. So her parents took her to their doctor.  After multiple tests, she was diagnosed with Non-Hodgkin's Lymphoma, a blood cancer.  Before long Audrey started experiencing significant treatment side effects, including heart and neurologic problems, landing her in the ICU with an uncertain prognosis. 

Audrey is not alone. More than 72,000 individuals in the US will be diagnosed with NHL in 2016.  Most will experience serious side effects, like Audrey, due to treatment.  Many will relapse with difficult to treat mutations.

 

We are here for them. We are here for Audrey.

 
 
Audrey Blue 16-9.jpg
 

Created in 2015, on research from world leading chemist Dr. Jindřich “Henry” Kopeček, our polymer antibody conjugate platform uses a unique mechanism of action to crosslink cell receptors, providing transformative solutions for patients, oncologists, and payers.

 
Artboard 15.jpg

HOW IT WORKS

Cells talk...A Lot.


Every cell in your body needs to communicate, to keep its neighbors up to date. Much of this communication occurs by proteins that stay on the cell's surface, cell receptors. These communication signals can be subverted when disease occurs. At Bastion, we have discovered a way to hijack these cell receptors: changing their communication to eliminate cancers, autoimmune, and neurologic diseases.

 

learn how receptor crosslinking is disrupting oncology

 

Meet the Team

Executive Management

 
OLIN BECK CEO, Founder

OLIN BECK

CEO, Founder

PHILLIP H. GRIMM President, COO, Founder

PHILLIP H. GRIMM

President, COO, Founder

DANIEL GARNER CTO, Founder

DANIEL GARNER

CTO, Founder

VISHAL KAPOOR Chief Business Officer

VISHAL KAPOOR

Chief Business Officer

 

Advisory Board

 

DR. JINDŘICH (HENRY) KOPEČEK

Chief Scientific Advisor

World Leader in Biopolymer Chemistry

 

DR. PAUL SHAMI

Chief Medical Advisor

Leader in Blood Cancer Drug Development

DR. JANE YANG

Polymer & Conjugation Advisor

Polymer Scale Up Specialist

DR. DAVE HOBSON

Regulatory Advisor

Leader in FDA Relations

DR. DAVID NOWOTNIK

Product Development Advisor

Leader in Polymer Drug Development

Artboard 15.png